Selective killing of leukemia and lymphoma cells ectopically expressing hCGβ by a conjugate of curcumin with an antibody against hCGβ subunit

Oncology

Volumn 76, Issue 2, 2009, Pages 101-111

  Vyas, Hemant K ^a   Pal, Rahul ^a   Vishwakarma, Ram ^a   Lohiya, Nirmal K ^b   Talwar, G P ^a,c  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^b UNIVERSITY OF RAJASTHAN   (India)

^c Research Foundation E 8   (India)

Author keywords

Acute myeloid leukemia; Curcumin antibody conjugate; Histiocytic lymphoma; Human chorionic gonadotropin beta; MOLT 4; T lymphoblastic leukemia; U 937

Indexed keywords

ANTIBODY CONJUGATE; CHORIONIC GONADOTROPIN ANTIBODY; CHORIONIC GONADOTROPIN BETA SUBUNIT; CPIPP ANTIBODY; CPIPP ANTIBODY CURCUMIN CONJUGATE; CURCUMIN; MICROSOMAL AMINOPEPTIDASE; PROPIDIUM IODIDE; TRYPAN BLUE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; ASSAY; CELL CULTURE; CELL GROWTH; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG CONJUGATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKOCYTE; LYMPHOMA CELL; MICROSCOPY; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL; STAINING;

AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL SEPARATION; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; CURCUMIN; DRUG DESIGN; FEMALE; HUMANS; LEUKEMIA; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES, MONONUCLEAR; LYMPHOMA; MALE; MIDDLE AGED; TETRAZOLIUM SALTS; THIAZOLES; U937 CELLS;

EID: 58149157482     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000188665     Document Type: Article

References (41)

1. Sahraoui S, Hassani AT, Ouhtatou F, Acharki A, Benider A, Kahlain A: Pure choriocarcinoma of the testis; report of a case and review of the literature. Ann Urol (Paris) 2001;35:125-128.
2. Weiss S, Amit A, Schwartz MR, Kalpna AL: Primary choriocarcinoma of the vulva. Int J Gynecol Cancer 2001;11:251-254.
3. Szturmowicz M, Slodkowska J, Zych J, Rudzinski P, Sakowicz A, Rowinska-Zakrzewska E: Frequency and clinical significance of beta-subunit human chorionic gonadotropin expression in non-small cell lung cancer patients. Tumor Biol 1999;20:99-104.
4. Iles RK, Persad R, Trivedi M, Sharma KB, Dickinson A, Smith P, et al: Urinary concentration of human chorionic gonadotropin and its fragments as a prognostic marker in bladder cancer. Br J Urol 1996;77:61-69.
5. Lundin M, Nordling S, Carpelan-Holmstrom M, Louhimo J, Alfthan H, Stenman UH, et al: A comparison of serum and tissue hCG beta as prognostic markers in colorectal cancer. Anticancer Res 2000;20:4949-4951.
6. Rau B, Below C, Liebrich W, von Schilling C, Schlag PM: Significance of serum hCGβ as a tumor marker for stomach carcinoma. Langenbecks Arch Chir 1995;380:359-364.
7. Louhimo J, Nordling S, Alfthan H, von Boguslawski K, Stenman UH, Haglund C: Specific staining of human chorionic gonadotropin beta in benign and malignant gastrointestinal tissues with monoclonal antibodies. Histopathology 2001;38:418-424.
8. Alfthan H, Haglund C, Roberts P, Stenman UH: Elevation of free beta subunit of human chorionic gonadotropin and core beta fragment of human chorionic gonadotropin in the serum and urine of patients with malignant pancreatic and biliary diseases. Cancer Res 1992;52:4628-4633.
9. Bièche I, Lazar V, Noguès C, Poynard T, Giovangrandi Y, Bellet D, et al: Prognostic value of chorionic gonadotropin beta gene transcripts in human breast carcinoma. Clin Cancer Res 1998;4:671-676.
10. Crawford RA, Iles RK, Carter PG, Caldwell CJ, Shepherd JH, Chard T: The prognostic significance of beta human chorionic gonadotropin and its metabolites in women with cervical carcinoma. J Clin Pathol 1998;51:685-688.
11. Hedström J, Grenman R, Ramsay H, Finne P, Lundin J, Haglund C, et al: Concentration of free hCGbeta subunit in serum as a prognostic marker for squamous-cell carcinoma of the oral cavity and oropharynx. Int J Cancer 1999;84:525-528.
12. Bhalang K, Kafrawy AH, Miles DA: Immunohistochemical study of the expression of human chorionic gonadotropin-beta in oral squamous cell carcinoma. Cancer 1999;85:757-762.
13. Scholl, PD, Jurco S, Austin JR: Ectopic production of beta-HCG by a maxillary squamous cell carcinoma. Head Neck 1997;19:701-705.
14. de Bruijn HW, ten Hoor KA, Krans M, van der Zee AG: Rising serum values of beta-subunit human chorionic gonadotropin (hCG) in patients with progressive vulvar carcinomas. Br J Cancer 1997;75:1217-1218.
15. Carter PG, Iles RK, Neven P, Ind TE, Shepherd JH, Chard T: Measurement of urinary beta core fragment of human chorionic gonadotropin in women with vulvo-vaginal malignancy and its prognostic significance. Br J Cancer 1995;71:350-353.
16. Sheaff MT, Martin JE, Badenoch, DF, Baithun SI: Beta hCG as a prognostic marker in adenocarcinoma of the prostate. J Clin Pathol 1996;49:693-694.
17. Jiang Y, Zeng F, Xiao C, Liu J: Expression of beta-human chorionic gonadotropin genes in renal cell cancer and benign renal disease tissues. J Huazhong Univ Sci Technol Med Sci 2003;23:291-293.
18. Hotakainen K, Ljungberg B, Paju A, Rasmuson T, Alfthan H, Stenman UH: The free beta-subunit of human chorionic gonadotropin as a prognostic factor in renal cell carcinoma. Br J Cancer 2002;86:185-189.
19. Senba M, Watanabe M: Ectopic production of beta-subunit of human chorionic gonadotropin in malignant lymphoma. Zentralbl Pathol 1991;137:402-404.
20. Leong M, English M, McMullan D, Ramani P: Aberrant expression of beta-hCG in anaplastic large cell lymphoma. Pediatr Dev Pathol 2008;11:230-234.
21. Fraternali-Orcioni G, Falini B, Quaini F, Campo E, Piccioli M, Gamberi B, Pasquinelli G, Poggi S, Ascani S, Sabattini E, Pileri SA: Beta-hCG aberrant expression in primary mediastinal large B-cell lymphoma. Am J Surg Pathol 1999;23:717-721.
22. Kathuria S, Sriraman R, Nath R, Sack M, Pal R, Artsaenko O, et al: Efficacy of plant produced recombinant antibodies against hCG. Hum Reprod 2002;17:2054-2061.
23. Kabeer RS, Pal R, Talwar GP: Human acute lymphoblastic leukemia cells make human pregnancy hormone hCG and expose it on the membrane: a case for using recombinant antibody against hCG for selective delivery of drugs and/or radiations. Curr Sci 2005;89:1571-1576.
24. Sundstrom C, Nilsson K: Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976;17:565-577.
25. Brunning RD, Matutes E, Borowitz M, Flandrin G, Head D, Vardiman J, Bennet J: Acute myeloid leukemia; in Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001, pp 75-107.
26. Gupta SK, Ramakrishnan S, Talwar GP: Properties and characteristics of an anti-hCG monoclonal antibody. J Biosci 1982;4:105-106.
27. Kathuria S, Nath R, Pal R, Singh O, Fischer R, Lohiya NK, et al: Functional recombinant antibodies against hCG expressed in plants. Curr Sci 2002;82:1452-1457.
28. Talwar GP, Gupta R, Gupta SK, Malhotra R, Khanna R, Mitra DK, et al: A monoclonal antibody cytolytic to androgen independent DU145 and PC3 human prostatic carcinoma cells. Prostate 2001;46:207-213.
29. Drewe E, Powell RJ: Clinically useful monoclonal antibodies in treatment. J Clin Pathol 2002;55:81-85.
30. Telli ML, Hunt SA, Carlson RW, Guardino AE: Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007;25:3525-3533.
31. Knauer M, Haid A, Ammann K, et al: Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome. World J Surg Oncol 2007;5:114.
32. Iles RK: Ectopic hCGβ expression by epithelial cancer: malignant behavior, metastasis and inhibition of tumor cell apoptosis. Mol Cell Endocrinol 2007;260-262:264-270.
33. Gelderman KA, Tomlinson S, Ross GD, Gorter A: Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 2004;25:158-164.
34. Srimal RC, Dhawan BN: Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol 1973;25:447-452.
35. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB: Curcumin downregulates cell survival mechanisms in human prostate cancer lines. Oncogene 2001;20:7597-7609.
36. Cheng AL, Hsu CH, Lin JK, et al: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res 2001;21:2895-2900.
37. Aggarwal BB, Shishodia S: Suppression of the nuclear factor-kappa B activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann NY Acad Sci 2004;1030:434-441.
38. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB: Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of I kappa B alpha kinase and Akt activation. Mol Pharmacol 2006;69:195-206.
39. Ireson CR, Jones DJL, Orr S, et al: Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 2002;11:105-111.
40. Suresh D, Srinivasan K: Studies on the in vitro absorption of spice principles - curcumin, capsaicin and piperine in rat intestines. Food Chem Toxicol 2007;45:1437-1442.
41. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS: Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998;64:353-356.